Please login to the form below

Not currently logged in
Email:
Password:

Aquapharm awarded GBP 4m funding

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Aquapharm develops antiinfectives from microscopic marine elements and is also developing anti-ageing treatments through advanced fermentation technology.

Shareholders in the company include Scottish and Argyll and Islands Enterprise have also increased investment in Aquapharm.

The company has built up a library of over 6500 marine bacteria and fungi and is using the microorganisms to look for products, such as new antibiotics and "functional" foods with health-giving benefits, such as anti-oxidants.

Dr Simon Barnes, managing partner of Tate & Lyle Ventures, said that Aquapharm had an unrivalled ability to develop natural marine-derived ingredients for a wide range of functional food applications and nutraceuticals, in an interview with a local newspaper.

25th July 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics